1. Shahrizaila N, Lehmann HC, Kuwabara S. Guillain-barré syndrome. Lancet. 2021; 397(10280): 1214-28. doi.10.1016/S0140-6736(21)00517-1 PMid:33647239

2. Willison HJ, Jacobs BC, van Doorn PA. Guillain-barre syndrome. Lancet. 2016; 388(10045):717-27. doi.10.1016/S0140-6736(16)00339-1 PMid:26948435

3. Tonekaboni SH, Mahmoudi S, Gorji FA, Biglari HN, Taghdiri MM, Etemadi K, et al. Epidemiology of Guillain-Barré Syndrome in Iranian children aged 0-15 years (2008-2013). Iran J Child Neurol. 2021; 15(4):27. doi.10.22037/ijcn.v15i4.25087 PMID: 34782839 PMCID: PMC8570621

4. Hosseininezhad M, Khatami SS, Saadat S, Asghari M, Ghovvati Choshal H, Hooshmand Marvasti A, et al. Ten years evaluation of epidemiology- and mortality-related factors in adults and children with Guillain-Barré syndrome in the north of Iran. Neurol Sci. 2022; 43(3):1929-38. doi.10.1007/s10072-021-05562-y PMid:34403028 PMCid:PMC8369876

5. Klein J, Samuels MA. Adams and Victor's Principles of Neurology. New York: McGraw-Hill Educ; 2014.

6. Van den Berg B, Walgaard C, Drenthen J, Fokke C, Jacobs BC, Van Doorn PA. Guillain-Barré syndrome: pathogenesis, diagnosis, treatment and prognosis. Nat Rev Neurol. 2014; 10(8): 469-82. doi.10.1038/nrneurol.2014.121 PMid:25023340

7. Hughes RA, Swan AV, Van Doorn PA. Intravenous immunoglobulin for Guillain‐Barré syndrome. Cochrane Database Syst Rev. 2014; (9): CD002063. doi. 10.1002/14651858.CD002063.pub6 PMid:25238327 PMCid:PMC6781841

8. Abu-Rumeileh S, Abdelhak A, Foschi M, Tumani H, Otto M. Guillain-Barré syndrome spectrum associated with COVID-19: an up-to-date systematic review of 73 cases. J Neurol. 2021; 268(4):1133-70. doi.10.1007/s00415-020-10124-x PMid:32840686 PMCid:PMC7445716

9. Toscano G, Palmerini F, Ravaglia S, Ruiz L, Invernizzi P, Cuzzoni MG, et al. Guillain-Barré syndrome associated with SARS-CoV-2. N Engl J Med. 2020; 382(26):2574-6. doi.10.1056/NEJMc2009191 PMid:32302082 PMCid:PMC7182017

10. Hafsteinsdóttir B, Dalemo E, Elíasdóttir Ó, Ólafsson E, Axelsson M. Decreased incidence of Guillain-Barré syndrome during the COVID-19 pandemic: a retrospective population-based study. Neuroepidemiology. 2023; 57(1):1-6. doi. 10.1159/000527726 PMID: 36366822 PMCID: PMC9892998

11. Filosto M, Piccinelli SC, Gazzina S, Foresti C, Frigeni B, Servalli MC, et al. Guillain-Barré syndrome and COVID-19: an observational multicentre study from two Italian hotspot regions. J Neurol Neurosurg Psychiatry. 2021; 92(7):751-6. doi.10.1136/jnnp-2020-324837 PMid:33158914

12. Carrillo-Larco RM, Altez-Fernandez C, Ravaglia S, Vizcarra JA. COVID-19 and Guillain-Barre syndrome: a systematic review of case reports. Wellcome Open Res. 2020; 5:107. doi.10.12688/wellcomeopenres.15987.1 PMid:32995555 PMCid:PMC7509591

13. Dalakas MC. Guillain-Barré syndrome: the first documented COVID-19-triggered autoimmune neurologic disease: more to come with myositis in the offing. Neurol Neuroimmunol Neuroinflamm. 2020; 7(5): e781. doi.10.1212/NXI.0000000000000781 PMid:32518172 PMCid:PMC7309518

14. Keddie S, Pakpoor J, Mousele C, Pipis M, Machado PM, Foster M, et al. Epidemiological and cohort study finds no association between COVID-19 and Guillain-Barré syndrome. Brain. 2021;144(2):682-93. doi.10.1093/brain/awaa433 PMid:33313649 PMCid:PMC7799186

15. Keh RY, Scanlon S, Datta-Nemdharry P, Donegan K, Cavanagh S, Foster M, et al. COVID-19 vaccination and Guillain-Barré syndrome: analyses using the National Immunoglobulin Database. Brain. 2023; 146(2):739-48. doi.10.1093/brain/awac446 PMid:36458975

16. Dimachkie MM, Barohn RJ. Guillain-Barré syndrome and variants. Neurol Clin. 2013; 31(2):491-510. doi.10.1016/j.ncl.2013.01.005 PMid:23642721 PMCid:PMC3939842

17. Korinthenberg R, Trollmann R, Felderhoff-Müser U, Bernert G, Hackenberg A, Hufnagel M, et al. Diagnosis and treatment of Guillain-Barré syndrome in childhood and adolescence: an evidence- and consensus-based guideline. Eur J Paediatr Neurol. 2020; 25:5-16. doi.10.1016/j.ejpn.2019.12.005 PMid:31879224

18. Caress JB, Castoro RJ, Simmons Z, Scelsa SN, Lewis RA, Ahlawat A, et al. COVID‐19-associated Guillain‐Barré syndrome: the early pandemic experience. Muscle Nerve. 2020;62(4):485-91. doi.10.1002/mus.27024 PMid:32678460 PMCid:PMC7405390

19. Zhao H, Shen D, Zhou H, Liu J, Chen S. Guillain-Barré syndrome associated with SARS-CoV-2 infection: causality or coincidence? Lancet Neurol. 2020; 19(5): 383-4. doi.10.1016/S1474-4422(20)30109-5 PMid:32246917

20. Rajabally YA, Durand MC, Mitchell J, Orlikowski D, Nicolas G. Electrophysiological diagnosis of Guillain-Barré syndrome subtype: could a single study suffice? J Neurol Neurosurg Psychiatry. 2015; 86(1):115-9. doi.10.1136/jnnp-2014-307815 PMid:24816419

21. Tsagkaris C, Bilal M, Aktar I, Aboufandi Y, Tas A, Aborode AT, et al. Cytokine storm and neuropathological alterations in patients with neurological manifestations of COVID-19. Curr Alzheimer Res. 2022; 19(9):641-57.doi.10.2174/1567205019666220908084559 PMid:36089786

22. Gupta A, Paliwal VK, Garg RK. Is COVID-19-related Guillain-Barré syndrome different? Brain Behav Immun. 2020;87:177-8. doi.10.1016/j.bbi.2020.05.061 PMid:32464156 PMCid:PMC7247496

23. Hasan I, Saif-Ur-Rahman KM, Hayat S, Papri N, Jahan I, Azam R, et al. Guillain‐Barré syndrome associated with SARS‐CoV‐2 infection: a systematic review and individual participant data meta‐analysis. J Peripher Nerv Syst. 2020; 25(4): 335-43. doi.10.1111/jns.12419 PMid:33112450

24. Jacobs B, Rothbarth P, Van der Meché F, Herbrink P, Schmitz P, De Klerk M, et al. The spectrum of antecedent infections in Guillain-Barré syndrome: a case-control study. Neurology. 1998; 51(4):1110-5. doi.10.1212/WNL.51.4.1110 PMid:9781538

25. Gutiérrez-Ortiz C, Méndez-Guerrero A, Rodrigo-Rey S, San Pedro-Murillo E, Bermejo-Guerrero L, Gordo-Mañas R, et al. Miller Fisher syndrome and polyneuritis cranialis in COVID-19. Neurology. 2020; 95(5): 601-5. doi.10.1212/WNL.0000000000009619 PMID: 32303650